Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-2,200
Closed -$1K 4957
2022
Q2
$1K Sell
2,200
-100
-4% -$2.77K ﹤0.01% 4518
2022
Q1
$9K Buy
+2,300
New +$89.6K ﹤0.01% 3678
2021
Q1
Sell
-800
Closed -$2K 5677
2020
Q4
$2K Buy
+800
New +$46.4K ﹤0.01% 4114
2020
Q3
Sell
-700
Closed -$2K 4716
2020
Q2
$2K Buy
+700
New +$19.9K ﹤0.01% 3731
2019
Q3
Sell
-300
Closed -$2K 4115
2019
Q2
$2K Buy
+300
New +$9.6K ﹤0.01% 3519
2018
Q4
Sell
-100
Closed -$1K 3974
2018
Q3
$1K Buy
+100
New +$1.87K ﹤0.01% 3713

Other funds holding CDNA

Cutler Group's CDNA Position: Q2 2022 in Review

Cutler Group sold out of CareDx (CDNA) in Q2 2022, closing a stake of 100 shares — an estimated $2.77K sold.

Cutler Group first reported a position in CDNA in Q3 2018 and held it in 9 quarters. The position peaked at $44K in Q1 2019. 184 funds tracked by Wall St. Rank hold CDNA as of Q2 2022.

  • Cutler Group reported no remaining CareDx position as of Q2 2022 after selling out during the quarter.
  • Cutler Group sold 100 CareDx shares in Q2 2022, an estimated $2.77K.
  • Cutler Group first reported a position in CareDx in Q3 2018 and held it in 9 quarters.
  • Cutler Group's CareDx position peaked at $44K in Q1 2019.
  • 184 funds tracked by Wall St. Rank held CareDx as of Q2 2022.

Based on Cutler Group's 13F filing for Q2 2022, filed 4 Aug 2022.